Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure - Wikidata - awgldk - TriplyDB

Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure

Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure

http://www.wikidata.org/entity/Q28748219

about

sameAs

Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis Inhibition of cardiac sympathetic afferent reflex and sympathetic activity by baroreceptor and vagal afferent inputs in chronic heart failure Combining angiotensin receptor blockers with ACE inhibitors in elderly patients Association of plasma angiotensin-(1-7) level and left ventricular function in patients with type 2 diabetes mellitus An index for characterization of natural and non-natural amino acids for peptidomimetics Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence?Chronic heart failure: current evidence, challenges to therapy, and future directions.Heart failure in hypertension: prevention and treatment.When conventional heart failure therapy is not enough: angiotensin receptor blocker, direct renin inhibitor, or aldosterone antagonist?Renin-angiotensin system blocking drugs.Novel blockers of the renin-angiotensin-aldosterone system in chronic heart failure.Modulation of the renin-angiotensin-aldosterone system in heart failure.Beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, nitrate-hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID(2) ): an evidence-based mnemonic for the treatment of systolic heart Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?Combining angiotensin-receptor blockers with angiotensin-converting-enzyme inhibitors Of fads, fashion, surrogate endpoints and dual RAS blockade.Aldosterone antagonists: evidence-based yet underutilized effective heart failure therapy.

P2860

Q26767278-7219A1CC-5376-40D5-A00E-D462A5DC07E0 Q30239022-B054942F-CA76-40CD-B12C-F01B923D7803 Q31032570-83F90772-7B70-413F-A768-0476A50411A5 Q33830694-1C934D78-93A0-40D2-B310-FC06AEC0F5B9 Q34729883-A46948FA-7418-425D-B034-81F6FEFECFAA Q34917849-61C534F2-927E-46E7-BAEF-C581B6799993 Q36263401-55D19848-7F78-421F-9BB9-A2395F181BA4 Q37053287-35EC8138-2DB8-409F-9454-828AEFB75F8B Q37880858-18C8A8CF-5979-498A-B6F9-20E1731A90EE Q38022713-D8B283E0-F16C-4B7D-91EE-8223C6AFC3B4 Q38067485-ABAB3B5D-A6A3-4969-9153-5D0719FC18AB Q38137851-1B6D296E-55F5-4B55-8563-466CBF16D027 Q38162791-4DAAAFA4-59CE-4791-A13F-5A88E9EB94B4 Q38186633-14CCB6E9-8703-4531-832B-8DB3D046EEEB Q38537344-10B06CC3-B015-4FE1-B0BB-356140425222 Q39416346-A045B341-2BD3-469B-8F3F-AEDC8FE15ACF Q42045329-D3482239-B990-45C6-83CF-7DEAA3E24416 Q42946303-A526E6BB-1AAC-4544-BC4C-3F681637D4C7 Q46215805-FD7EDC36-FDE5-46F9-9BD8-91A9EA6E7E1B

P2860

Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure

http://www.wikidata.org/entity/Q28748219

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Meta-analysis of combined ther ...... in patients with heart failure

@ast

Meta-analysis of combined ther ...... in patients with heart failure

@en

Meta-analysis of combined ther ...... in patients with heart failure

@nl

type

label

Meta-analysis of combined ther ...... in patients with heart failure

@ast

Meta-analysis of combined ther ...... in patients with heart failure

@en

Meta-analysis of combined ther ...... in patients with heart failure

@nl

prefLabel

Meta-analysis of combined ther ...... in patients with heart failure

@ast

Meta-analysis of combined ther ...... in patients with heart failure

@en

Meta-analysis of combined ther ...... in patients with heart failure

@nl

P1433

Q28748219-F7A2D45B-15F0-40B3-B756-399CBB5CF9B3

P1476

Q28748219-0A1CEB50-3660-442C-873B-5701BFA0340E

P2093

Q28748219-2911C6EF-2261-4687-BBF2-C9F4D8933701

Q28748219-3016A7C3-1506-4A43-A7FC-D743C67060EB

Q28748219-3763F832-81AE-40E9-9175-5B6F209DA8AE

Q28748219-770CD9DE-8EA7-4906-8B02-4366F874D6AF

Q28748219-92ADDABB-82AC-43E5-A8B0-90E83E153E99

Q28748219-9A051A7F-B1D6-45D5-B6B8-408ABFE2C199

Q28748219-9D6BF5B0-A9C4-43B2-9F12-F34A32469C29

Q28748219-CDF6C909-68F2-4F34-872B-21F382CF5882

Q28748219-EAB92CC5-2BD8-4945-9DEB-40DC5A5252ED

P2860

Q28748219-0B3821DD-7E30-465E-BF56-5181498707B6

Q28748219-0F17CA3D-2FC7-4F37-949D-983AD1E43936

Q28748219-17BB0EA1-7685-4F27-8D81-3DC7D89B6B0C

Q28748219-1D0AD2EE-9597-49DC-BF29-B2B95CAA2FB7

Q28748219-200FCF18-B8E9-45C3-B5EB-F480F63DBE05

Q28748219-2601D45D-8336-401D-B87C-F64FA44FEFBA

Q28748219-3E4D43F8-8636-445E-AC95-98247834BB4A

Q28748219-3F971CC4-FC69-42B8-BDF6-62A0C543E987

Q28748219-4D03624B-D9AF-4060-958C-3984A229C617

Q28748219-5293F1DA-3B06-448C-BE4B-89578D0C9677

P304

Q28748219-63C827A6-136E-4F2F-A122-B04453A284E3

P31

Q28748219-51C5BED9-EE0E-406F-AE52-F93B89A7C8E3

Q28748219-B95446A8-156E-4AD2-A815-05F19C922477

P356

Q28748219-E71079DD-0BB2-46D8-B9FC-C3F670B892D6

P407

Q28748219-197FF8CB-B14B-4969-BADA-A49BC475353C

P433

Q28748219-015E5572-AD7D-4584-9219-B5AF624A3D3F

P478

Q28748219-A928AAE4-2A72-41A3-87EF-91C9E3DA18A0

P577

Q28748219-57341E8F-DF5F-4206-A7F2-F0A181A1F9FC

P5875

Q28748219-9ED2C8B2-DE50-4D01-AF91-AC703387E89C

P698

Q28748219-42BE9979-EC3F-4BBC-BAFA-F7446C55482F

P921

Q28748219-88E82FA8-32E6-444C-B548-B92CF62E751A

P932

Q28748219-480807E5-F1BF-4278-B7B0-72B04DF87718

P356

JOURNAL.PONE.0009946

P1433

P1476

Meta-analysis of combined ther ...... in patients with heart failure

@en

P2093

Alain J Nordmann

http://www.w3.org/2001/XMLSchema#string

Andrea Kuenzli

http://www.w3.org/2001/XMLSchema#string

Gregory Arutiunov

http://www.w3.org/2001/XMLSchema#string

Heiner C Bucher

http://www.w3.org/2001/XMLSchema#string

Inder Anand

http://www.w3.org/2001/XMLSchema#string

Leo C Kum

http://www.w3.org/2001/XMLSchema#string

Michel White

http://www.w3.org/2001/XMLSchema#string

Rizwan Afzal

http://www.w3.org/2001/XMLSchema#string

Robert McKelvie

http://www.w3.org/2001/XMLSchema#string

P2860

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 G

Measuring inconsistency in meta-analyses

Quantifying heterogeneity in a meta-analysis

Meta-analysis in clinical trials

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

The hazards of scoring the quality of clinical trials for meta-analysis

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group.

Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure.

P304

e9946

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0009946

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43074254

http://www.w3.org/2001/XMLSchema#string

P698

20376345

http://www.w3.org/2001/XMLSchema#string

P921

P932

2848587

http://www.w3.org/2001/XMLSchema#string